Title |
Role of zoledronic acid in the prevention and treatment of osteoporosis
|
---|---|
Published in |
Clinical Interventions in Aging, March 2011
|
DOI | 10.2147/cia.s7282 |
Pubmed ID | |
Authors |
Louis-Georges Ste-Marie, Ages Rakel, Andree Boucher, Louis-Georges Ste-Marie |
Abstract |
Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Unknown | 92 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 13 | 14% |
Student > Ph. D. Student | 12 | 13% |
Researcher | 11 | 12% |
Student > Master | 11 | 12% |
Other | 10 | 11% |
Other | 17 | 18% |
Unknown | 19 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 39% |
Biochemistry, Genetics and Molecular Biology | 11 | 12% |
Agricultural and Biological Sciences | 6 | 6% |
Engineering | 6 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Other | 9 | 10% |
Unknown | 21 | 23% |